LGND News and Press, Ligand Pharmaceuticals Incorporated From 05/04/22

Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2022 and provided an operating forecast and program updates. Ligand management will host a conf...

COLUMBUS, Ohio, April 28, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated metastatic breast and gynecological cancers, today announced two abstracts accepted for presenta...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, May 4, 2022 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will in...

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that on April 8, 2022, the Human Capital Management and Compensation Committee of Ligand’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 40,000 shares of its common stock...

Ligand Pharmaceuticals is an intriguing business with a differentiated business model. The company has seen many moving parts, both on the buy and sell side of the business. I like the promise of the business, but execution is not convincing in recent times. While I see appeal...

Berkshire Hathaway to acquire all outstanding Alleghany shares for $848.02 per share in cash, for a total equity value of approximately $11.6 billion. This is one of the five largest acquisitions in Berkshire's history and it ends Buffett's six-year drought of large acquisitions. ...

A new Special Purpose Acquisition Corp. arrangement may open the door to more successful SPAC mergers. The deal, once completed, involves a pharmaceutical company spinning off a division, which will then be acquired by the SPAC. There are several positive aspects for the shareholders of the or...

Ligand Pharmaceuticals (LGND) signs merger agreement with Avista Public Acquisition (AHPAU) a SPAC, providing for the spin-off of OmniAb, Ligand’s antibody discovery business, immediately followed by a merger with a newly formed subsidiary of APAC. The combined company will b...

Transaction will result in OmniAb becoming an independent publicly traded company Ligand’s shareholders to receive 100% of Ligand’s shares in OmniAb through a tax-free distribution immediately prior to the merger Ligand Pharmaceuticals Incorporated (Lig...

Ligand Pharmaceuticals Incorporated (LGND) Q4 2021 Earnings Conference Call February 17, 2022 04:30 PM ET Company Participants Simon Latimer - Head of Investor Relations John Higgins - Chief Executive Officer Matt Korenberg - Chief Financial Officer Matt Foehr - Chief Operating Officer Confer...